TY  - CHAP
M1  - Book, Section
TI  - Screening for Cancer and Cardiovascular
A1  - Gonzalez, Alex
A2  - Keuroghlian, Alex S.
A2  - Potter, Jennifer
A2  - Reisner, Sari L.
PY  - 2022
T2  - Transgender and Gender Diverse Health Care: The Fenway Guide
AB  - Heart  disease  and  cancer  are  the  two  leading  causes  of  death  in  the  general  population  in  the  United  States,1  but  their  impact  on  transgender  and  gender  diverse  (TGD)  people  is  poorly  understood.  Gender-affirming  hormone  therapy  (GAHT)  can  play  a  role  in  the  development  of  certain  cancers,  and  may  worsen  some  risk  factors  for  cardiovascular  disease.  Societal  and  health  care  sector  marginalization  of  TGD  people—via  economic  disenfranchisement,  increased  risky  behavior,  decreased  access  to  care,  decreased  patient  willingness  to  seek  care,  and  increased  stigma—can  contribute  to  higher  oncologic  and  cardiovascular  risk  as  well.  This  chapter  will  review  what  we  know  about  cancer  and  cardiovascular  disease  epidemiology  in  TGD  people  as  well  as  how  to  approach  screening  for  these  diseases  in  a  primary  care  setting.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/25
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184177127
ER  -